Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival.
Tyler C HaddadSongzhu ZhaoMingjia LiSandip H PatelAndrew JohnsMadison GroganGabriella LopezAbdul MiahLai WeiGabriel TinocoBrian RiesenbergZihai LiAlexa MearaErin M BertinoKari KendraGregory OttersonCarolyn J PresleyDwight H OwenPublished in: Cancer immunology, immunotherapy : CII (2021)
Unlike other irAEs, we found that irTCP was associated with worse overall survival. The incidence of irTCP appeared lowest among those treated with PD-1/L1 monotherapy.